Adjuvant Capital
27
34M
18
2.25
2
0.33
2
- Stages of investment
- Areas of investment
Summary
Adjuvant Capital is the famous VC, which was founded in 2012. The leading representative office of defined VC is situated in the New York. The fund was located in North America if to be more exact in United States.
The important activity for fund was in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations.
The current fund was established by Charlie Petty, Glenn Rockman, Kabeer Aziz.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight X-Vax Technology, Themis Bioscience, InDevR. Among the most popular fund investment industries, there are Biotechnology, Health Care. The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Adjuvant Capital, startups are often financed by aws Gru00fcnderfonds (aws Founders Fund), Wellington Partners, Ventech. The meaningful sponsors for the fund in investment in the same round are aws Gru00fcnderfonds (aws Founders Fund), Wellington Partners, Ventech.
Investments analytics
Analytics
- Total investments
- 27
- Lead investments
- 2
- Exits
- 2
- Rounds per year
- 2.25
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (26)
- Health Care (18)
- Medical (7)
- Life Science (7)
- Genetics (5) Show 14 more
- Investments by region
-
- United States (16)
- China (1)
- United Kingdom (1)
- Denmark (2)
- Belgium (2) Show 2 more
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 6M
- Group Appearance index
- 0.85
- Avg. company exit year
- 11
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| 54gene | 16 Sep 2021 | Biotechnology, Health Care, Genetics, Life Science | Early Stage Venture | 25M | United States, District of Columbia, Washington |
| CopperEgg Corporation | 12 Jul 2011 | Software, SaaS, Enterprise Software, Cloud Computing, Enterprise Applications | Early Stage Venture | 2M | United States, Texas, Austin |
| Memo Therapeutics | 02 Nov 2023 | Biotechnology, Collaboration | Late Stage Venture | 27M | Switzerland, Zurich, Zurich |
| PayDownHero | 30 Mar 2020 | Software, Financial Services, FinTech, Finance, Apps | Seed | 302K | United States, Massachusetts, Boston |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.